Dr. Lea N. Baer, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 357
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 263795 -
Medical Oncology Physician
NY license 263795 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Suny/stony Brook University Hospital Stony Brook, NY
Medical groups
- Stony Brook Internists University Faculty Practice Corporation (428 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 357
- Services billed
- 797
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 280 | 184 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 217 | 72 |
| Established patient office or other outpatient visit, 30-39 minutes | 136 | 60 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 66 | 59 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 64 | 34 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 40 | 40 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Stony Brook, NY | 361 |
| Letrozole Other prescribers in Stony Brook, NY | 43 |
| Exemestane | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $154 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $70.21 |
|---|---|
| Daiichi Sankyo Inc. | $57.27 |
| Merck Sharp & Dohme LLC | $26.59 |
| Food and Beverage | $154 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $236,045 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.